Nasacort (Triamcinolone Acetonide)

Triamcinolone acetonide is a glucocorticoid that binds to intracellular receptors in nasal mucosal cells. This interaction modifies gene expression, decreasing the production of inflammatory mediators and thereby reducing swelling and irritation in the nasal passages.

The appropriate dose of Nasacort is determined by a qualified healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and not exceed the recommended number of sprays.

Safety data for Nasacort in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To request Nasacort, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasacort contains triamcinolone acetonide, a potent intranasal glucocorticoid, offering anti‑inflammatory effects comparable to other prescription steroids but is available over‑the‑counter in many regions. Its efficacy and safety profile are similar to other OTC steroid sprays such as fluticasone propionate, though individual response may vary.

Store Nasacort at room temperature, preferably below 25 °C. Keep the spray in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed to maintain product stability.

Nasacort is administered as a nasal spray. The patient gently shakes the bottle, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include nasal septal perforation, severe allergic reactions such as anaphylaxis, adrenal suppression with prolonged high‑dose use, and opportunistic fungal infections of the nasal mucosa. Any signs of these conditions should prompt immediate medical attention.

Nasacort should be avoided in individuals with known hypersensitivity to triamcinolone acetonide or any component of the formulation. Patients with active untreated nasal infections, recent nasal surgery, or those who require systemic corticosteroid therapy without medical supervision should also refrain from use.